Millennium Management LLC reduced its stake in shares of Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) by 25.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 808,058 shares of the company’s stock after selling 276,363 shares during the quarter. Millennium Management LLC owned 0.63% of Synthetic Biologics worth $410,000 as of its most recent SEC filing.
Separately, Citadel Advisors LLC boosted its stake in Synthetic Biologics by 312.1% in the fourth quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock valued at $122,000 after buying an additional 183,120 shares in the last quarter.
Synthetic Biologics stock opened at $0.25 on Friday. Synthetic Biologics, Inc. has a 12 month low of $0.23 and a 12 month high of $0.27.
Several analysts recently weighed in on SYN shares. Zacks Investment Research raised Synthetic Biologics from a “sell” rating to a “hold” rating in a research note on Saturday, February 24th. Griffin Securities lowered Synthetic Biologics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $2.63.
Synthetic Biologics Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.